APL2 — Competitive Intelligence Brief

APL2 (APL2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Complement C3 inhibitor. Area: Immunology.

phase 2 Complement C3 inhibitor Complement component C3 Immunology Small molecule

Target snapshot

APL2 (APL2) — Apellis Pharmaceuticals, Inc.. APL2 is a complement C3 inhibitor that blocks the central component of the complement cascade to reduce inflammation and tissue damage.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
APL2 TARGET	APL2	Apellis Pharmaceuticals, Inc.	phase 2	Complement C3 inhibitor	Complement component C3
Izervay™	Izervay™	Hoffmann-La Roche	marketed	Complement C3 inhibitor	Complement C3
ALXN1850	ALXN1850	Alexion Pharmaceuticals, Inc.	phase 3	Complement C3 inhibitor	Complement C3
ALXN2060	ALXN2060	Alexion Pharmaceuticals, Inc.	phase 3	Complement C3 inhibitor	Complement C3
APL-2	APL-2	Apellis Pharmaceuticals, Inc.	phase 3	Complement C3 inhibitor	Complement C3
APL-2, Pegcetacoplan	APL-2, Pegcetacoplan	Apellis Pharmaceuticals, Inc.	phase 3	Complement C3 inhibitor	Complement C3
Placebo matching Pegcetacoplan	Placebo matching Pegcetacoplan	Swedish Orphan Biovitrum	phase 3	Complement C3 inhibitor (aptamer)	Complement C3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Complement C3 inhibitor class)

1. Apellis Pharmaceuticals, Inc. · 3 drugs in this class
2. Alexion Pharmaceuticals, Inc. · 2 drugs in this class
3. Hoffmann-La Roche · 1 drug in this class